AbCellera Biologics (ABCL) Income towards Parent Company (2020 - 2026)
AbCellera Biologics (ABCL) posted Income towards Parent Company of -$43.2 million for Q1 2026, down 382.56% on a QoQ basis from -$8.9 million in Q4 2025, and up 5.38% year-over-year from -$41.0 million in Q1 2025.
AbCellera Biologics (ABCL) Income towards Parent Company (2020 - 2026) Analysis & Trends
AbCellera Biologics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$43.2 million for Q1 2026.
- Quarterly Income towards Parent Company rose 5.38% year-over-year to -$43.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$144.0 million (up 14.24% YoY) and the FY2025 annual result came in at -$146.4 million, up 10.1% from the prior year.
- Income towards Parent Company was -$43.2 million for Q1 2026 at AbCellera Biologics, down from -$8.9 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $168.6 million in Q1 2022 and bottomed at -$57.1 million in Q3 2025.
- A 5-year average of -$20.0 million and a median of -$34.7 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company jumped 224.53% — and 2023, when it slumped 349.93%.
- AbCellera Biologics' Income towards Parent Company stood at -$29.9 million in 2022, then tumbled by 57.73% to -$47.2 million in 2023, then advanced by 27.44% to -$34.2 million in 2024, then jumped by 73.85% to -$8.9 million in 2025, then sank by 382.56% to -$43.2 million in 2026.
- Business Quant data shows ABCL's Income towards Parent Company at -$43.2 million in Q1 2026, -$8.9 million in Q4 2025, and -$57.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | AbCellera Biologics | 1.62 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.17 Mn |
| Dec 31, 2025 | -8.95 Mn |
| Sep 30, 2025 | -57.12 Mn |
| Jun 30, 2025 | -34.73 Mn |
| Mar 31, 2025 | -45.62 Mn |
| Dec 31, 2024 | -34.21 Mn |
| Sep 30, 2024 | -51.11 Mn |
| Jun 30, 2024 | -36.93 Mn |
| Mar 31, 2024 | -40.61 Mn |
| Dec 31, 2023 | -47.15 Mn |
| Sep 30, 2023 | -28.61 Mn |
| Jun 30, 2023 | -30.53 Mn |
| Mar 31, 2023 | -40.11 Mn |
| Dec 31, 2022 | -29.89 Mn |
| Sep 30, 2022 | 26.62 Mn |
| Jun 30, 2022 | -6.79 Mn |
| Mar 31, 2022 | 168.57 Mn |
| Dec 31, 2021 | 59.95 Mn |
| Sep 30, 2021 | -21.38 Mn |
| Jun 30, 2021 | -2.32 Mn |